Related Experiment Videos
Lessons from a pilot study of transfer factor in chronic fatigue syndrome
C De Vinci1, P H Levine, G Pizza
1Immunodiagnosis and Immunotherapy Unit, 1st Division of Urology Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Biotherapy (Dordrecht, Netherlands)
|January 1, 1996
Abstract:
Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial.